Conjupro Biotherapeutics

Focus: Conjupro Biotherapeutics is an early-stage oncology-focused biotech company based in Princeton, NJ specializing in small molecules and antibody-drug conjugates (ADCs). The company operates across oncology, respiratory, and cardiovascular therapeutic areas with a pre-clinical to Phase 2 pipeline.

Oncology Respiratory Cardiovascular

Profile data last refreshed 2d ago · AI intelligence enriched 2w ago

Open Jobs

About Conjupro Biotherapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Conjupro Biotherapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

0/9 — Limited

Company HealthSolid

Pipeline

Early-stage

10 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

JMT108

Cancer

Phase 1

SYS6043

Cancer

Phase 1

CPO301

Cancer

Help build intelligence for Conjupro Biotherapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Portfolio breadth across oncology ADCs and small molecules positions you in high-value therapeutic modalities with strong market validation
Early-stage company structure offers rare opportunity to shape scientific strategy and see direct impact on pipeline advancement
Multi-indication pipeline (solid tumors, lymphomas, asthma, hypertension) provides exposure across diverse oncology and non-oncology programs

Watch Out For

No marketed products or revenue means zero commercial validation; all pipeline assets remain pre-clinical or Phase 1/2, creating significant technical and financial risk
Zero active job postings and missing funding/employee data suggest company may be in stealth mode, dormant, or facing capital constraints that limit hiring and stability

Generated by Claude from Conjupro Biotherapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

HA115

Asthma

Phase 1

Levamlodipine, Amlodipine

Hypertension

Phase 1

CPO-100

Solid Tumor

Phase 1

CPO102

Pancreatic Cancer

Phase 1